Article

MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck

University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, Pennsylvania 15213-1863, USA.
Cancer (Impact Factor: 4.9). 04/2011; 117(7):1454-62. DOI: 10.1002/cncr.25689
Source: PubMed

ABSTRACT The overall 5-year survival rate of approximately 60% for head and neck cancer patients has remained essentially unchanged over the past 30 years. MicroRNA-137 (miR-137) plays an essential role in cell-cycle control at the G1/S-phase checkpoint. However, the aberrant miR-137 promoter methylation observed in squamous cell carcinoma of the head and neck (SCCHN) suggests a tumor-specific molecular defect that may contribute to disease progression.
The goal of this study was to assess, in formalin-fixed, paraffin-embedded tumor tissue, the association between miR-137 promoter methylation and survival (both overall and disease free) and with prognostic factors including stage, tumor size, lymph node positivity, tumor grade, and surgical tumor margin positivity.
The promoter methylation status of miR-137 was ascertained by methylation-specific polymerase chain reaction and detected in 11 of 67 SCCHN patients (16.4%), with no significant differences according to site (oral cavity, pharynx, larynx). Methylation of the miR-137 promoter was significantly associated with overall survival (hazard ratio, 3.68; 95% confidence interval, 1.01-13.38) but not with disease-free survival or any of the prognostic factors evaluated.
The results of this study indicate that miR-137 is methylated in tumor tissue from pharyngeal and laryngeal squamous cancers, in addition to oral squamous cell carcinoma, and that miR-137 promoter methylation has potential utility as a prognostic marker for SCCHN.

Download full-text

Full-text

Available from: William A LaFramboise, Aug 18, 2015
0 Followers
 · 
133 Views
  • Source
    • "Since the first paper on miR-137 and its target MITF in melanoma was published in 2008 (Bemis et al., 2008), there has been an increasing interest in the role of miR-137 in the development and progression of different tumor entities. Several targets of miR-137 have been identified in various types of cancer, which indicates a tumor-suppressive function for miR-137 (Silber et al., 2008; Langevin et al., 2011; Chen et al., 2011a; Liu et al., 2011). The current study correlates miR-137 expression with melanoma patients' outcome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs are small noncoding RNAs that regulate gene expression and have important roles in various types of cancer. Previously, miR-137 was reported to act as a tumor suppressor in different cancers, including malignant melanoma. In this study, we show that low miR-137 expression is correlated with poor survival in stage IV melanoma patients. We identified and validated two genes (c-Met and YB1) as direct targets of miR-137 and confirmed two previously known targets, namely enhancer of zeste homolog 2 (EZH2) and microphthalmia-associated transcription factor (MITF). Functional studies showed that miR-137 suppressed melanoma cell invasion through the downregulation of multiple target genes. The decreased invasion caused by miR-137 overexpression could be phenocopied by small interfering RNA knockdown of EZH2, c-Met, or Y box-binding protein 1 (YB1). Furthermore, miR-137 inhibited melanoma cell migration and proliferation. Finally, miR-137 induced apoptosis in melanoma cell lines and decreased BCL2 levels. In summary, our study confirms that miR-137 acts as a tumor suppressor in malignant melanoma and reveals that miR-137 regulates multiple targets including c-Met, YB1, EZH2, and MITF.Journal of Investigative Dermatology advance online publication, 15 November 2012; doi:10.1038/jid.2012.357.
    Journal of Investigative Dermatology 11/2012; 133(3). DOI:10.1038/jid.2012.357 · 6.37 Impact Factor
  • L Dou · D Zheng · J Li · Y Li · L Gao · L Wang · L Yu
    [Show abstract] [Hide abstract]
    ABSTRACT: Fusion proteins containing the amino terminus of mixed lineage leukemia (MLL) are common in acute lymphoblastic leukemia (ALL) due to translocations. The MLL-AF4 fusion protein is generated by the translocation t(4;11)(q21;q23), and t(4;11)-positive ALL patients (MLL-AF4 ALL), have a notoriously poorer prognosis compared with patients with other MLL-associated leukemias. The detailed role of this fusion protein in leukemogenesis is not well understood. MicroRNAs (miRNAs) targeting the AF4 3' untranslated regions may modulate MLL-AF4 fusion protein levels, raising the question of whether regulation of these miRNAs are involved in the progression of MLL-AF4 ALL. In this study, we show that miR-143 was identified as a regulator of MLL-AF4 expression in MLL-AF4 ALL samples. Restoration of miR-143 in MLL-AF4-positive RS4;11 and MV4-11 cells induced apoptosis, negatively contributing to leukemia cell growth by reducing MLL-AF4 fusion protein levels. Furthermore, miR-143 was epigenetically repressed by promoter hypermethylation in MLL-AF4-positive primary blasts and cell lines, but not in normal bone marrow cells and MLL-AF4-negative primary blasts, which was directly associated with expression of the MLL-AF4 oncogene. This is the first study to show that miR-143 functions as a tumor suppressor in MLL-AF4 B-cell ALL. These data reveal the therapeutic promise of upregulating miR-143 expression for MLL-AF4 B-cell ALL.
    Oncogene 06/2011; 31(4):507-17. DOI:10.1038/onc.2011.248 · 8.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs, miRs) are small, non-coding RNA molecules that regulate gene expression posttranscriptionally. Although discovered only recently in the early 1990s, this relatively new group of molecules has already been proven to play an essential role in the regulation of many physiological and, most importantly, pathological processes such as cancer. A large number of miRNAs has been found to be involved in the pathogenesis of various human malignancies, and expression of miRNAs has been demonstrated to correlate with clinic and outcome. In tumors of the brain, however, the investigations on the role of miRNAs are still in its infancy, and most publications refer to the most common primary brain tumor, the glioma (mostly glioblastoma). But despite the fact that there is only limited data available so far, these first results are very promising and implicate that miRNAs might open a new perspective for diagnostics and treatment of this disease. With this review article, we aim to provide a short overview of miRNA biogenesis, function and regulation in general. Thereafter, the clinical relevant data about miRNAs in the two most common primary malignant brain tumors in adults (glioblastomas) and children (medulloblastomas) will be summarized, and their potential impact on diagnostics and treatment will be highlighted.
    Molecular Neurobiology 07/2011; 44(3):223-34. DOI:10.1007/s12035-011-8197-x · 5.29 Impact Factor
Show more